Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EMN 2018 | Novel avenues for MM treatment: CAR T-cells, venetoclax, induction & MRD

Nikhil Munshi • 19 Apr 2018
EMN 2018
Multiple Myeloma Bortezomib CAR-T Venetoclax

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting novel avenues for multiple myeloma (MM) therapy from the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy. Dr Munshi covers BCMA-targeting CAR T-cells, venetoclax, induction regimens and measurable residual disease monitoring.

More from Nikhil Munshi

The interaction between bone marrow stromal cells and tumor cells as a potential target in WM 1:32
The interaction between bone marrow stromal cells and tumor cells as a potential target in WM
Nikhil Munshi • 19 Oct 2024
Immunotherapies in the future treatment landscape for Waldenström’s macroglobulinemia 1:04
Immunotherapies in the future treatment landscape for Waldenström’s macroglobulinemia
Nikhil Munshi • 19 Oct 2024
The potential of early intervention for high-risk patients with Waldenström’s macroglobulinemia 0:47
The potential of early intervention for high-risk patients with Waldenström’s macroglobulinemia
Nikhil Munshi • 19 Oct 2024
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma 1:56
Long noncoding RNAs represent potential therapeutic targets in multiple myeloma
Nikhil Munshi • 11 Dec 2023

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals